查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1874004

细胞株开发市场

Cell Line Development Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

2024年细胞株开发市场价值为77.7亿美元，预计到2031年将成长至186.2亿美元，2031年至2031年的复合年增长率预计为13.3%。细胞株工程的持续创新和细胞株技术的重大进步预计将成为该市场的主要趋势。

细胞株开发市场分析

细胞系建构对于评估毒性、进行体外试验以及确定新药疗效至关重要。这个过程最大限度地降低了临床试验中药物失败的风险，从而节省了时间、金钱和资源。在细胞株建构过程中，会生产重组蛋白，包括疫苗、融合蛋白、生长因子、酵素、双特异性抗体和单株抗体，以及用于开发癌症免疫疗法的创新方法。研究人员正在探索如何简化生物治疗药物发现和候选药物筛选的早期阶段，以降低细胞株的相关成本。这个高效过程能够快速生成并筛选出大量生产高品质重组蛋白的细胞系，同时儘早淘汰活性较低的克隆候选株。细胞株建构技术的进步加快了各种候选药物在初始阶段的测试，从而节省了时间和成本。

此外，参与药物研发和细胞株开发的公司之间的合作正在进一步推动产业发展。例如，Cytiva 最近收购了德国领先的病毒载体和高性能细胞系生产技术供应商 CEVEC Pharmaceuticals。 2022 年 7 月，Bio-Techne Corporation 宣布完成对 Namocell, Inc. 的收购。 Namocell 提供简单的单细胞分选和分装平台，能够维持细胞的活力和完整性。 Namocell 的工具和耗材是生物治疗和诊断相关工作流程中的关键技术，包括细胞和基因疗法的开发和商业化、细胞工程、细胞株开发、单细胞基因组学、抗体发现、合成生物学和稀有细胞分离。

细胞株开发市场概览

细胞系开发是指选择细胞机制来生产治疗性生物製剂或其他有价值的蛋白质的过程。多种表现系统，包括酵母菌、哺乳动物、植物和细菌，均可用于细胞系开发。中国仓鼠卵巢 (CHO) 细胞通常在悬浮培养中生长，是生产复杂蛋白质最常用的细胞系，随后在生产阶段被送入生物反应器中。细胞株开发的初步步骤是小规模悬浮培养，最终过渡到大规模生物反应器进行生产。细胞系在治疗产品开发中的应用正在改变生物製药行业的方方面面，从创新基因疗法的研发到先进疫苗和癌症治疗药物的生产，从而创造了巨大的市场机会。

战略洞察

细胞株开发市场的驱动因素与机会

提高疫苗产量以促进市场成长

为因应疫苗产品日益增长的需求，人们开发了多种大规模生产抗原蛋白的方法。疫苗研发人员通常遵循线性流程，包括全面的资料分析和验证，以降低以往较高的失败率。主要的疫苗和抗病毒药物生产商正积极研发生产大流行候选疫苗和季节性流感疫苗的新策略。此前，大部分研发工作都集中在开发已获许可的鸡蛋培养疫苗。为了满足即将到来的季节性流感疫苗接种需求，并为临床试验生产大流行疫苗原型，生产商正在提升产能，并实现鸡蛋培养疫苗技术中许多以往需要人工操作步骤的自动化。因此，疫苗产量的增加可能会推动细胞株开发市场的成长。

新兴市场蕴藏着巨大机会

随着生物製剂和生物相似药日益受到关注，生产中对细胞系的需求也随之增长。透过与政府机构、生物技术公司和学术机构的合作，可以促进该领域的研究和开发。此外，印度拥有技术娴熟的劳动力，且研发成本远低于西方国家，因此是开展细胞株开发活动的理想之地。例如，印度政府透过生物技术部 (DBT)、印度医学研究理事会 (ICMR) 和科学技术部 (DST) 等国家级资助机构，支持发展中国家的细胞株开发。

细胞株开发市场区隔分析

细胞株开发市场分析的关键细分市场包括类型、产品和应用。

  • 市场按类型分为原代细胞系、杂交瘤、连续细胞系和重组细胞系，其中重组细胞株在 2023 年占据最大的市场份额。
  • 按产品划分，市场分为设备、培养基和试剂，其中培养基和试剂部分在 2023 年占最大份额。
  • 按应用领域划分，市场分为药物发现、生物生产和组织工程，其中生物生产领域在 2023 年占据最大份额。

细胞株开发市场的地理分析

细胞株开发市场报告的地理范围分为五个区域：北美、亚太、欧洲、中东和非洲以及南美/南美和中美洲。

北美一直是细胞株开发市场的领导地区，其中美国在2023年仍是最大的市场。美国细胞株开发市场的成长归功于众多产业参与者的存在以及重塑市场格局的动态变化。主要市场参与者、学术和研究机构广泛的研发活动，以及生物製药和生物技术公司对创新产品日益增长的需求，都在推动北美市场的成长。此外，公共和私营部门对基因组研究的大量投入，以及医疗保健领域对先进方法整合的日益重视，以及政府和私人机构为促进精准医疗而采取的倡议，预计将进一步推动北美细胞株开发市场的成长并创造可观的收入。由于众多支持透过生物工程技术创造、发现或改造各种生物分子和生物体的开发措施和商业策略，医疗生物技术领域经历了革命性的变化。生技新创企业革命也使拥有创新理念的新兴公司受益，提高了收入，并巩固了北美在全球细胞株开发市场中的地位。

细胞株开发市场报告范围

细胞株开发市场的最新发展

细胞株开发市场评估是透过收集一手和二手研究的定性和定量资料进行的，这些数据包括重要的企业出版物、协会资料和资料库。以下是细胞株开发市场的一些最新发展和策略：

  • 2023年1月16日，Abzena公司发表了全新的细胞株开发（CLD）平台AbZelect和AbZelectPRO，旨在加速抗体和重组蛋白生产细胞系的建构。这些平台旨在促进复杂生物药物计画快速推进至临床试验和新药研究申请（IND）提交阶段。 （资料来源：Abzena公司，新闻稿，2023年）
  • 龙沙公司推出了全新的GS Effex细胞株，用于开发效力更强的治疗性抗体。该细胞株的研发旨在满足市场对更高效治疗性抗体的日益增长的需求。 GS Effex细胞株，可无缝整合到龙沙的现有平台中，具有良好的细胞生长性能，并能够生产效力更强的治疗性抗体，从而为从药物发现到商业化生产的整个治疗开发过程提供解决方案。 （资料来源：龙沙公司，新闻稿，2023年）

细胞株开发市场报告的覆盖范围和交付成果

这份题为《细胞株开发市场规模及预测（2021-2031）》的报告对市场进行了全面分析，涵盖以下领域：

  • 涵盖范围内所有关键细分市场的全球、区域和国家层面的市场规模和预测
  • 市场动态，例如驱动因素、限制因素和关键机会
  • 未来主要趋势
  • 详细的PEST/波特五力模型与SWOT分析
  • 全球及区域市场分析，重点在于关键市场趋势、主要参与者、法规及最新发展。
  • 产业格局和竞争分析，包括市场集中度、热力图分析、主要参与者和最新发展动态
  • 深入的公司概况

目录

第一章：引言

第二章：细胞株开发市场及主要结论

第三章：研究方法

  • 覆盖范围
  • 二手研究
  • 初步研究

第四章：细胞株开发与市场概况

  • 概述
  • PEST分析
    • 北美细胞株开发市场：PEST分析
    • 欧洲细胞株开发市场：PEST分析
    • 亚太地区细胞系开发市场：PEST分析
    • 中东和非洲细胞株开发市场：PEST分析
    • 细胞株开发市场及南美洲及中美洲PEST分析
  • 专家意见

第五章：全球细胞株开发市场及主要市场动态

  • 主要市场驱动因素
    • 再生医学的日益普及
    • 癌症发生率上升
    • 製药及生技公司加大研发投入
  • 关键限制
    • 细胞株污染相关的风险
  • 关键机会
    • 中等收入国家创造发展机会
  • 未来趋势
    • 药物发现活动中的持续研究
  • 影响分析

第六章：细胞株开发市场及全球分析

  • 全球细胞株开发市场收入预测与分析
  • 全球细胞株开发市场（依地域划分）－预测与分析
  • 关键参与者的市场定位
    • 默克集团
    • 赛默飞世尔科技公司

第七章：细胞株开发市场－2031年收入及预测与类型

  • 概述
  • 全球细胞株开发市场（按类型划分），2024 年和 2031 年（市场占有率百分比）
  • 原代细胞株
    • 概述
    • 全球原代细胞株市场收入及至2031年预测
  • 杂交瘤
    • 概述
    • 全球杂交瘤市场收入及预测至2031年
  • 连续性细胞系
    • 概述
    • 全球连续细胞系市场收入及预测（至2031年）
  • 重组细胞株
    • 概述
    • 全球重组细胞株市场收入及预测（至2031年）

第八章：细胞株开发市场分析及至2031年的预测及产品

  • 概述
  • 全球细胞株开发市场（按产品划分），2024 年和 2031 年（市场占有率百分比）
  • 装置
    • 概述
    • 全球设备市场收入及至2031年预测
  • 介质和试剂
    • 概述
    • 全球媒体及试剂市场收入及至2031年预测

第九章：细胞株开发市场分析及至2031年的预测与应用

  • 概述
  • 2024 年和 2031 年全球细胞株开发市场份额（按应用领域划分）
  • 药物发现
    • 概述
    • 全球药物研发市场收入及至2031年预测
  • 生物生产
    • 概述
    • 全球生物生产市场收入及至2031年预测
  • 组织工程
    • 概述
    • 全球组织工程市场收入及至2031年预测

第十章：细胞株开发市场收入及至2031年预测及地理分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • MEA
    • 阿联酋
    • 沙乌地阿拉伯
    • 南非
  • 南美洲和中美洲
    • 巴西
    • 阿根廷

第十一章：新冠疫情对全球细胞株开发市场的影响

  • 北美洲
  • 欧洲
  • 亚太
  • 世界其他地区

第十二章：细胞株开发市场－产业概况

  • 概述
  • 市场中各公司采取的成长策略（%）
  • 市场中各公司所进行的有机发展
  • 市场上各公司进行的非有机成长

第十三章：细胞株开发市场及主要公司概况

  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Sartorius AG
  • SELEXIS
  • BioFactura, Inc.
  • WuXi AppTec
  • LakePharma, Inc.
  • General Electric
  • Lonza
  • Corning Incorporated

第十四章：附录

简介目录
Product Code: TIPHE100001196

The cell line development market was valued at US$ 7.77 billion in 2024 and is projected to grow to US$ 18.62 billion by 2031, with an anticipated CAGR of 13.3% from 2031 to 2031. Continuous innovations in cell line engineering and significant advancements in cell line technology are expected to be prominent trends in the market.

Analysis of the Cell Line Development Market

Cell line development is essential for evaluating toxicity, conducting in-vitro tests, and determining the efficacy of new drug discoveries. This process minimizes the risk of drug failure during clinical trials, thereby saving time, money, and resources. During cell line development, recombinant proteins are produced, which include vaccines, fusion proteins, growth factors, enzymes, bi-specific and monoclonal antibodies, as well as innovative methods for creating cancer immunotherapies. Researchers are exploring ways to streamline the early stages of biotherapeutic discovery and candidate selection to lower the costs associated with cell line development. This efficient process quickly generates and selects cell lines that produce high-quality recombinant proteins in large quantities while eliminating less viable clone candidates as early as possible. Technological advancements in cell line development have expedited the testing of various drug candidates in the initial phases, resulting in time and cost savings.

Moreover, companies involved in drug discovery and cell line development are collaborating, which is further propelling the industry. For instance, Cytiva recently acquired CEVEC Pharmaceuticals, a leading German technology provider for producing viral vectors and high-performance cell lines. In July 2022, Bio-Techne Corporation announced the complete acquisition of Namocell, Inc., which offers simple single-cell sorting and dispensing platforms that maintain cell viability and integrity. Namocell's tools and consumables are vital technologies in various workflows related to biotherapeutics and diagnostics, including the development and commercialization of cell and gene therapies, cell engineering, cell line development, single-cell genomics, antibody discovery, synthetic biology, and rare cell isolation.

Overview of the Cell Line Development Market

Cell line development refers to the process of selecting cellular machinery to produce therapeutic biologics or other valuable proteins. Various expression systems, including yeast, mammals, plants, and bacteria, can be utilized to develop cell lines. Chinese hamster ovary (CHO) cells, typically grown in suspension cultures, are the most commonly used for producing complex proteins, which are later utilized in bioreactors during the manufacturing phase. The initial step in cell line development involves small-scale suspension cultures, which eventually transition to large-scale bioreactors for production. The application of cell lines in generating therapeutic products is transforming every aspect of the biopharmaceutical industry, from the creation of innovative gene therapies to the production of advanced vaccines and cancer treatments, thereby creating significant market opportunities.

Strategic Insights

Drivers and Opportunities in the Cell Line Development Market

Increasing Vaccine Production to Boost Market Growth

In response to the rising demand for vaccine products, various methods for producing large quantities of antigenic proteins have been developed. Vaccine developers typically follow a linear process that includes comprehensive data analysis and validation to mitigate historically high failure rates. Major vaccine and antiviral drug manufacturers are actively working on new strategies for producing pandemic candidates and seasonal influenza vaccines. Until recently, most efforts focused on developing licensed egg-based vaccines. To meet the demands of upcoming seasonal campaigns and to create pandemic vaccine prototypes for clinical trials, manufacturers are enhancing production capacities and automating many previously manual steps in egg-based vaccine technology. Consequently, the increase in vaccine production is likely to drive growth in the cell line development market.

Significant Opportunities in Emerging Markets

As biologics and biosimilars gain more attention, the need for cell lines in production is increasing. Research and development opportunities in this area can be fostered through collaborations with government initiatives, biotech firms, and academic institutions. Additionally, India is an attractive location for cell line development activities due to its skilled workforce and lower development costs compared to Western countries. For example, the Indian government supports cell line development in developing nations through national funding organizations such as the Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), and the Department of Science and Technology (DST).

Segmentation Analysis of the Cell Line Development Market

Key segments contributing to the analysis of the cell line development market include type, product, and application.

  • The market is segmented by type into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines, with the recombinant cell line segment holding the largest market share in 2023.
  • By product, the market is divided into equipment, media, and reagents, with the media and reagent segment capturing the largest share in 2023.
  • By application, the market is categorized into drug discovery, bioproduction, and tissue engineering, with the bioproduction segment holding the largest share in 2023.

Geographical Analysis of the Cell Line Development Market

The geographic scope of the cell line development market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has been the leading region in the cell line development market, with the US being the largest market in 2023. The growth of the US cell line development market is attributed to the presence of various industry players and the dynamic conditions that have reshaped the market landscape. Key market players, extensive research and development activities by academic and research institutions, and a rising demand for innovative products from biopharmaceutical and biotechnology companies are driving growth in North America. Additionally, significant funding for genomic research from both public and private sectors, along with an increasing focus on integrating advanced methods in healthcare and government and private initiatives to promote precision medicine, are expected to further propel growth and generate substantial revenue for the North American cell line development market. The medical biotechnology sector has undergone revolutions due to numerous development initiatives and business strategies that support the creation, discovery, or modification of diverse biomolecules and organisms through bioengineering techniques. The Biotech Startup Revolution has also benefited new companies with innovative ideas, enhancing revenue generation and strengthening North America's position in the global cell line development market.

Scope of the Cell Line Development Market Report

Recent Developments in the Cell Line Development Market

The cell line development market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the cell line development market:

  • On January 16, 2023, Abzena launched its new cell line development (CLD) platforms, AbZelect and AbZelectPRO, aimed at accelerating the generation of production cell lines for manufacturing antibodies and recombinant proteins. These platforms are designed to facilitate the rapid advancement of complex biologic drug programs towards clinical trials and investigational new drug (IND) application submissions. (Source: Abzena Company Name, Newsletter, 2023)
  • Lonza introduced its new GS Effex cell line for developing therapeutic antibodies with enhanced potency. This cell line was created to address the growing market demand for more sophisticated therapeutic antibodies. Derived from Lonza's leading GS Xceed cell line, GS Effex integrates seamlessly into Lonza's platforms, offering good cell growth and the capability to produce therapeutic antibodies with increased potency, thus providing a solution for therapeutic development from discovery to commercial manufacturing. (Source: Lonza Company Name, Press Release, 2023)

Coverage and Deliverables of the Cell Line Development Market Report

The report titled "Cell Line Development Market Size and Forecast (2021-2031)" offers a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis highlighting key market trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
  • In-depth company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Cell Line Development Market and By Type
    • 1.3.2 Global Cell Line Development Market and By Product
    • 1.3.3 Global Cell Line Development Market and By Application
    • 1.3.4 Global Cell Line Development Market and By Geography

2. Cell Line Development Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Cell Line Development and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Cell Line Development Market in North America: PEST Analysis
    • 4.2.2 Cell Line Development Market in Europe: PEST Analysis
    • 4.2.3 Cell line development Market in APAC: PEST Analysis
    • 4.2.4 Cell Line Development Market in MEA: PEST Analysis
    • 4.2.5 Cell Line Development Market and South and Central America PEST Analysis
  • 4.3 Expert Opinion

5. Global Cell Line Development Market and Key Market Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Increasing Adoption of Regenerative Medicines
    • 5.1.2 Rising Prevalence of Cancer
    • 5.1.3 Growing Investment in R and D by Pharmaceutical and Biotechnology Companies
  • 5.2 Key Restraints
    • 5.2.1 Risk Associated with Cell Line Contamination
  • 5.3 Key Opportunity
    • 5.3.1 Middle Income Countries Creating Development Opportunities
  • 5.4 Future Trend
    • 5.4.1 Consistent Research in Drug Discovery Activities
  • 5.5 Impact Analysis

6. Cell Line Development Market and Global Analysis

  • 6.1 Global Cell Line Development Market Revenue Forecast and Analysis
  • 6.2 Global Cell Line Development Market, By Geography - Forecast and Analysis
  • 6.3 Market Positioning of Key Players
    • 6.3.1 Merck KGaA
    • 6.3.2 Thermo Fisher Scientific Inc.

7. Cell Line Development Market - Revenue and Forecasts to 2031 and Type

  • 7.1 Overview
  • 7.2 Global Cell Line Development Market, by Type, 2024 and 2031 (% Share)
  • 7.3 Primary Cell Line
    • 7.3.1 Overview
    • 7.3.2 Global Primary Cell Line Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.4 Hybridomas
    • 7.4.1 Overview
    • 7.4.2 Global Hybridomas Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.5 Continuous Cell Lines
    • 7.5.1 Overview
    • 7.5.2 Global Continuous Cell Lines Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.6 Recombinant Cell Line
    • 7.6.1 Overview
    • 7.6.2 Global Recombinant Cell Line Market Revenue and Forecast to 2031 (US$ Mn)

8. Cell Line Development Market Analysis and Forecasts to 2031 and Product

  • 8.1 Overview
  • 8.2 Global Cell Line Development Market, by Product, 2024 and 2031 (% Share)
  • 8.3 Equipment
    • 8.3.1 Overview
    • 8.3.2 Global Equipment Market Revenue and Forecast to 2031 (US$ Mn)
  • 8.4 Media and Reagent
    • 8.4.1 Overview
    • 8.4.2 Global Media and Reagent Market Revenue and Forecast to 2031 (US$ Mn)

9. Cell Line Development Market Analysis and Forecasts to 2031 and Application

  • 9.1 Overview
  • 9.2 Global Cell Line Development Market Share by Application 2024 and 2031 (%)
  • 9.3 Drug Discovery
    • 9.3.1 Overview
    • 9.3.2 Global Drug Discovery Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.4 Bioproduction
    • 9.4.1 Overview
    • 9.4.2 Global Bioproduction Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.5 Tissue Engineering
    • 9.5.1 Overview
    • 9.5.2 Global Tissue Engineering Market Revenue and Forecast to 2031 (US$ Mn)

10. Cell Line Development Market Revenue and Forecast to 2031 and Geographical Analysis

  • 10.1 North America Cell Line Development Market, Revenue and Forecast to2031
    • 10.1.1 Overview
    • 10.1.2 North America Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.1.3 North America Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.1.4 North America Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.1.5 North America Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.1.6 North America Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.1.7 US
      • 10.1.7.1 US Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.1.7.2 US Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.1.7.3 US Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.1.7.4 US Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.1.8 Canada
      • 10.1.8.1 Canada Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.1.8.2 Canada Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.1.8.3 Canada Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.1.8.4 Canada Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.1.9 Mexico
      • 10.1.9.1 Mexico Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.1.9.2 Mexico Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.1.9.3 Mexico Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.1.9.4 Mexico Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.2 Europe Cell Line Development Market Revenue and Forecast to 2031
    • 10.2.1 Europe Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.2.2 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.2.3 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.2.4 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.5 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.2.6 Germany
      • 10.2.6.1 Germany Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.6.2 Germany Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.6.3 Germany Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.6.4 Germany Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.7 UK
      • 10.2.7.1 UK Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.7.2 UK Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.7.3 UK Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.7.4 UK Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.8 France
      • 10.2.8.1 France Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.8.2 France Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.8.3 France Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.8.4 France Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.9 Spain
      • 10.2.9.1 Spain Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.9.2 Spain Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.9.3 Spain Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.9.4 Spain Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.10 Italy
      • 10.2.10.1 Italy Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.10.2 Italy Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.10.3 Italy Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.10.4 Italy Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.3 APAC Cell Line Development Market, Revenue and Forecast to 2031
    • 10.3.1 Overview
    • 10.3.2 APAC Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.3.3 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.3.4 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.3.5 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.6 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.3.7 China
      • 10.3.7.1 China Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.7.2 China Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.7.3 China Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.7.4 China Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.8 Japan
      • 10.3.8.1 Japan Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.8.2 Japan Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.8.3 Japan Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.8.4 Japan Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.9 India
      • 10.3.9.1 India Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.9.2 India Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.9.3 India Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.9.4 India Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.10 South Korea
      • 10.3.10.1 South Korea Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.10.2 South Korea Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.10.3 South Korea Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.10.4 South Korea Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.11 Australia
      • 10.3.11.1 Australia Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.11.2 Australia Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.11.3 Australia Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.11.4 Australia Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.4 MEA Cell Line Development Market, Revenue and Forecast to 2031
    • 10.4.1 Overview
    • 10.4.2 MEA Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.4.3 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.4.4 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.4.5 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.4.6 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.4.7 UAE
      • 10.4.7.1 UAE Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.4.7.2 UAE Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.4.7.3 UAE Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.4.7.4 UAE Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.4.8 Saudi Arabia
      • 10.4.8.1 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.4.8.2 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.4.8.3 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.4.8.4 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.4.9 South Africa
      • 10.4.9.1 South Africa Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.4.9.2 South Africa Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.4.9.3 South Africa Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.4.9.4 South Africa Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.5 South and Central America Cell Line Development Market, Revenue and Forecast to 2031
    • 10.5.1 Overview
    • 10.5.2 South and Central America Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.5.3 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.5.4 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.5.5 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.5.6 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.5.7 Brazil
      • 10.5.7.1 Brazil Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.5.7.2 Brazil Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.5.7.3 Brazil Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.5.7.4 Brazil Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.5.8 Argentina
      • 10.5.8.1 Argentina Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.5.8.2 Argentina Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.5.8.3 Argentina Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.5.8.4 Argentina Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)

11. Impact Of COVID-19 Pandemic on Global Cell Line Development Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Cell Line Development Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in The Market, (%)
  • 12.3 Organic Developments Done by The Companies in the Market
  • 12.4 Inorganic Developments Done by The Companies in the Market

13. Cell Line Development Marketand Key Company Profiles

  • 13.1 Merck KGaA
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Financial Overview
    • 13.1.4 Product Portfolio
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Thermo Fisher Scientific, Inc.
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Financial Information
    • 13.2.4 Product /Services Portfolio
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sartorius AG
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Financial Overview
    • 13.3.4 Product Portfolio
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 SELEXIS
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Financial Overview
    • 13.4.4 Product/Service Portfolio
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 BioFactura, Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Financial Overview
    • 13.5.4 Product Portfolio
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 WuXi AppTec
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Financial Overview
    • 13.6.4 Service Portfolio
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 LakePharma, Inc.
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Financial Overview
    • 13.7.4 Product Portfolio
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 General Electric
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Financial Overview
    • 13.8.4 Product Portfolio
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Lonza
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Financial Information
    • 13.9.4 Product Portfolio
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Corning Incorporated
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Financial Overview
    • 13.10.4 Product Portfolio
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms